Tags

Type your tag names separated by a space and hit enter

Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles.
Gynecol Endocrinol. 2007 Jun; 23(6):338-42.GE

Abstract

A subtle rise in serum progesterone during the late follicular phase in patients undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycles is a frequent event that can decrease implantation and pregnancy rates in controlled ovarian hyperstimulation (COH) protocols that use a gonadotropin-releasing hormone (GnRH) antagonist. The aim of the present study was to evaluate the prevalence and effect of the subtle progesterone rise during COH with single-dose GnRH antagonist in combination with clomiphene citrate (CC) and human menopausal gonadotropins (hMG) in IVF or ICSI cycles. Ninety-five women undergoing COH with CC, hMG and a single 2.5 mg dose of the GnRH antagonist, cetrorelix, were enrolled in the study. Patients were grouped according to serum progesterone level on the day of human chorionic gonadotropin (hCG) administration (P < 1.2 ng/ml or P >/= 1.2 ng/ml). The incidence of a subtle progesterone rise was 54.7% (52/95). The group with P >/= 1.2 ng/ml had significantly higher serum levels of luteinizing hormone (p = 0.002) and estradiol (p < 0.001) on the day of hCG injection than the group with P < 1.2 ng/ml, and more oocytes were retrieved (p = 0.001). However, there was no significant difference in fertilization, clinical pregnancy or implantation rate between the two groups. In conclusion, a subtle progesterone rise during the late follicular phase is common but not associated with pregnancy outcome.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17616858

Citation

Seow, Kok-Min, et al. "Subtle Progesterone Rise in the Single-dose Gonadotropin-releasing Hormone Antagonist (cetrorelix) Stimulation Protocol in Patients Undergoing in Vitro Fertilization or Intracytoplasmic Sperm Injection Cycles." Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, vol. 23, no. 6, 2007, pp. 338-42.
Seow KM, Lin YH, Huang LW, et al. Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles. Gynecol Endocrinol. 2007;23(6):338-42.
Seow, K. M., Lin, Y. H., Huang, L. W., Hsieh, B. C., Huang, S. C., Chen, C. Y., Chen, P. H., Tzeng, C. R., & Hwang, J. L. (2007). Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles. Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, 23(6), 338-42.
Seow KM, et al. Subtle Progesterone Rise in the Single-dose Gonadotropin-releasing Hormone Antagonist (cetrorelix) Stimulation Protocol in Patients Undergoing in Vitro Fertilization or Intracytoplasmic Sperm Injection Cycles. Gynecol Endocrinol. 2007;23(6):338-42. PubMed PMID: 17616858.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles. AU - Seow,Kok-Min, AU - Lin,Yu-Hung, AU - Huang,Lee-Win, AU - Hsieh,Bih-Chwen, AU - Huang,Shih-Chia, AU - Chen,Chin-Yu, AU - Chen,Pei-Hsin, AU - Tzeng,Chii-Ruey, AU - Hwang,Jiann-Loong, PY - 2007/7/10/pubmed PY - 2007/9/19/medline PY - 2007/7/10/entrez SP - 338 EP - 42 JF - Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology JO - Gynecol Endocrinol VL - 23 IS - 6 N2 - A subtle rise in serum progesterone during the late follicular phase in patients undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycles is a frequent event that can decrease implantation and pregnancy rates in controlled ovarian hyperstimulation (COH) protocols that use a gonadotropin-releasing hormone (GnRH) antagonist. The aim of the present study was to evaluate the prevalence and effect of the subtle progesterone rise during COH with single-dose GnRH antagonist in combination with clomiphene citrate (CC) and human menopausal gonadotropins (hMG) in IVF or ICSI cycles. Ninety-five women undergoing COH with CC, hMG and a single 2.5 mg dose of the GnRH antagonist, cetrorelix, were enrolled in the study. Patients were grouped according to serum progesterone level on the day of human chorionic gonadotropin (hCG) administration (P < 1.2 ng/ml or P >/= 1.2 ng/ml). The incidence of a subtle progesterone rise was 54.7% (52/95). The group with P >/= 1.2 ng/ml had significantly higher serum levels of luteinizing hormone (p = 0.002) and estradiol (p < 0.001) on the day of hCG injection than the group with P < 1.2 ng/ml, and more oocytes were retrieved (p = 0.001). However, there was no significant difference in fertilization, clinical pregnancy or implantation rate between the two groups. In conclusion, a subtle progesterone rise during the late follicular phase is common but not associated with pregnancy outcome. SN - 0951-3590 UR - https://www.unboundmedicine.com/medline/citation/17616858/Subtle_progesterone_rise_in_the_single_dose_gonadotropin_releasing_hormone_antagonist__cetrorelix__stimulation_protocol_in_patients_undergoing_in_vitro_fertilization_or_intracytoplasmic_sperm_injection_cycles_ L2 - https://www.tandfonline.com/doi/full/10.1080/09513590701403629 DB - PRIME DP - Unbound Medicine ER -